AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
IPO Year:
Exchange: NASDAQ
Website: axogeninc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/1/2024 | $13.00 | Outperform | Raymond James |
| 11/11/2022 | $15.00 | Buy | Jefferies |
| 5/9/2022 | $10.00 → $15.00 | Hold → Buy | Canaccord Genuity |
| 3/11/2022 | $21.00 | Overweight | Cantor Fitzgerald |
| 11/4/2021 | $25.00 → $20.00 | Market Outperform | JMP Securities |
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% in the third quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $4.1 million, or $0.10 per share in the third quarter of 2023.Adjusted
ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do s
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. "I am proud of the significant progress our team has made towards the regulatory transition of Avance from a tissue to a biologic," said Michael Dale, CEO and Director of Axogen, Inc. "We will continue to collaborate closely with the FDA as they review our application." The Company anticipates the FDA will notify the
ALACHUA, Fla. and TAMPA, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced today that it has granted an equity inducement award on September 3, 2024, to a new non-executive employee under the terms of the Axogen Inc.'s Inducement Equity Incentive Plan. The award was approved by the Compensation Committee of Axogen's Board of Directors in accordance with NASDAQ Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Axogen. The award consists of restricted stock units ("RSUs") representing 10,000 shares
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently, Kathleen P. Bloch, CytoSorbents' current CFO, announced her retirement from the Company effective as of the close of business today, and will continue to serve in an advisory role as a consultant to enable an effective t
The Board of Directors appoints Michael Dale as new CEO and Director, effective August 9, 2024Dale replaces Karen Zaderej, who will remain in an advisory role for nine monthsCurrent Member of the Board, Paul Thomas, will be the new Chairman of the Board, effective August 9, 2024 ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for n
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023.In the second quarter of 2024, our gross margin decreased to 73.8%, down from 77.7% in the second quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $6.7 million, or $0.1
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee. In connection with the commencement of employment on June 17, 2024, and as a material inducement of employment, an award was made under the Company's Inducement Equity Incentive plan consisting of restricted stock units ("RSUs") representing 10,000 shares of the Company's common stock. The RSUs are subject to vesting over 4 years, with 50% vesti
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S.
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
4 - Axogen, Inc. (0000805928) (Issuer)
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter Financial Results Third quarter revenue was $48.6 million, a 17.9% increase compared to the third quarter of 2023.In the third quarter of 2024, gross margin decreased to 74.9%, down from 76.8% in the third quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $4.1 million, or $0.10 per share in the third quarter of 2023.Adjusted
ALACHUA, Fla. and TAMPA, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2024 financial results on Thursday, November 7, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do s
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023.In the second quarter of 2024, our gross margin decreased to 73.8%, down from 77.7% in the second quarter of 2023.Net loss for the quarter was $1.9 million, or $0.04 per share, compared to net loss of $6.7 million, or $0.1
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the same quarter of the previous year.Net loss for the quarter was $6.6 million, or $0.15 per share, compared to net loss of $7.1 million, or $0.17 per share in the fir
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Results and Business Highlights Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the fourth quarter and grew mid-single digits versus the fourth quarter of 2022.The Company e
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2023 fourth quarter and full-year financial results on Tuesday, March 5, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Inte
ALACHUA, Fla. and TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2023. Third Quarter Financial Results Revenue was $41.3 million during the third quarter, an increase of approximately 12% over the third quarter of 2022.The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the third quarter and grew in the mid-single digit range versus the third quarter of 2022.The Company estimates that reve
ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may d
Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price Target of $13.
Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product. "Product innova
Canaccord Genuity analyst Caitlin Cronin reiterates Axogen (NASDAQ:AXGN) with a Buy and maintains $15 price target.
The company anticipates the BLA filing to be completed in the third quarter of 2024 and believe the procedural timelines for review combined with the rolling submission process will allow for approval around mid-2025.
Axogen (NASDAQ:AXGN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $41.378 million which missed the analyst consensus estimate of $41.964 million by 1.40 percent. This is a 12.86 percent increase over sales of $36.664 million the same period last year.
Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. Sophia Genetics posted GAAP loss of 37 cents per share, versus market expectations for a loss of 27 cents per share. The company’s quarterly sales came in at $17.05 million, missing estimates of $17.33 million. SOPHiA GENETICS shares tumbled 19% to $4.55 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Sunshine Biopharma, Inc. (NASDAQ:SBFM) climbed 146.3% to $0.1106 after dipping 19% on Monday. Sunshine Biopharma recently announced closing of $10.0 million underwritten public
10-Q - Axogen, Inc. (0000805928) (Filer)
8-K - Axogen, Inc. (0000805928) (Filer)
8-K - Axogen, Inc. (0000805928) (Filer)
S-8 - Axogen, Inc. (0000805928) (Filer)
8-K - Axogen, Inc. (0000805928) (Filer)
10-Q - Axogen, Inc. (0000805928) (Filer)
8-K - Axogen, Inc. (0000805928) (Filer)
8-K/A - Axogen, Inc. (0000805928) (Filer)
8-K - Axogen, Inc. (0000805928) (Filer)
10-Q - Axogen, Inc. (0000805928) (Filer)
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
SC 13G - Axogen, Inc. (0000805928) (Subject)
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
SC 13G - Axogen, Inc. (0000805928) (Subject)
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
SC 13G - Axogen, Inc. (0000805928) (Subject)
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
SC 13G/A - Axogen, Inc. (0000805928) (Subject)
SC 13G - Axogen, Inc. (0000805928) (Subject)
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently, Kathleen P. Bloch, CytoSorbents' current CFO, announced her retirement from the Company effective as of the close of business today, and will continue to serve in an advisory role as a consultant to enable an effective t
The Board of Directors appoints Michael Dale as new CEO and Director, effective August 9, 2024Dale replaces Karen Zaderej, who will remain in an advisory role for nine monthsCurrent Member of the Board, Paul Thomas, will be the new Chairman of the Board, effective August 9, 2024 ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for n
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales. In connection with the commencement of his employment on January 22, 2024, and as a material inducement of employment, Mr. Manning was awarded an equity grant on February 1, 2024, consisting of (i) non-qualified stock options to purc
ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that President and Chief Executive Officer (CEO) Karen Zaderej plans to retire from the Company by January 2025. The Company's Board of Directors will retain an executive recruitment firm to manage a search for her successor. When a new CEO is in place, Ms. Zaderej will step down from her executive post and Board duties and continue as a consultant to Axogen for an additional nine months to support the leadership transition and the submission process of the Biologics License Applicatio
ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ
ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience primarily in the life sciences industry, he replaces Peter Mariani, who will depart Axogen following a brief transition period. The move aligns the executive team with the Company's financial management and investor relations needs going forward as Axogen focuses on continued revenue growth across both business categories while drivin
ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations. Mr. Tamayo will report to Peter J. Mariani, Executive Vice President and Chief Financial Officer, and will be responsible for Financial Planning and Analysis and Investor Relations. Mr. Tamayo has over 20 years of experience in healthcare and life sciences including as a division CFO and in leadership
ALACHUA, Fla. and TAMPA, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Marc Began as Executive Vice President. Additionally, effective March 20, 2023, Mr. Began will be Axogen's General Counsel, replacing Brad Ottinger, General Counsel and Chief Compliance Officer. As a member of the executive leadership team, Mr. Began will report directly to Karen Zaderej, Chairman, CEO and President, and will be responsible for all legal, business development, and compliance activities for Axogen. "I want to thank Brad for his important contr
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketing Officer. Kemp brings more than 20 years of strategic marketing, sales, and business development experience in high-growing medical technology. As a member of the Axogen executive leadership team, Kemp will report directly to Karen Zaderej, Chairman, CEO and President, and will oversee the development and execution of the company's marketing strategies. "I am thrilled to welcome Jens to Axogen. Hi
DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i
Raymond James initiated coverage of AxoGen with a rating of Outperform and set a new price target of $13.00
Jefferies resumed coverage of AxoGen with a rating of Buy and set a new price target of $15.00
Canaccord Genuity upgraded AxoGen from Hold to Buy and set a new price target of $15.00 from $10.00 previously
Cantor Fitzgerald resumed coverage of AxoGen with a rating of Overweight and set a new price target of $21.00
JMP Securities reiterated coverage of Axogen with a rating of Market Outperform and set a new price target of $20.00 from $25.00 previously
Canaccord Genuity reiterated coverage of Axogen with a rating of Hold and set a new price target of $24.00 from $21.00 previously
SVB Leerink reiterated coverage of AxoGen with a rating of Outperform and set a new price target of $27.00 from $23.00 previously
Canaccord Genuity reiterated coverage of AxoGen with a rating of Hold and set a new price target of $21.00 from $20.00 previously
Canaccord Genuity resumed coverage of AxoGen with a rating of Hold
Canaccord Genuity reiterated coverage of Axogen with a rating of Hold and set a new price target of $21.00 from $20.00 previously